This systematic review assesses the safety and effectiveness of low-dose oral continuous combined hormone therapy (cc-HT) for managing climacteric symptoms in postmenopausal women. It finds that low-dose cc-HT effectively alleviates symptoms and prevents bone loss with a favorable safety profile, showing no increased risks for cardiovascular diseases or breast cancer.
